DE68923362T2 - Wachstumsregelfaktoren für neuriten. - Google Patents

Wachstumsregelfaktoren für neuriten.

Info

Publication number
DE68923362T2
DE68923362T2 DE68923362T DE68923362T DE68923362T2 DE 68923362 T2 DE68923362 T2 DE 68923362T2 DE 68923362 T DE68923362 T DE 68923362T DE 68923362 T DE68923362 T DE 68923362T DE 68923362 T2 DE68923362 T2 DE 68923362T2
Authority
DE
Germany
Prior art keywords
proteins
metalloproteases
present
neurites
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68923362T
Other languages
English (en)
Other versions
DE68923362D1 (de
Inventor
Martin Schwab
Pierenrico Caroni
Paolo Paganetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZUERICH ERZIEHUNGSDIREKTION
Original Assignee
ZUERICH ERZIEHUNGSDIREKTION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/401,212 external-priority patent/US5684133A/en
Application filed by ZUERICH ERZIEHUNGSDIREKTION filed Critical ZUERICH ERZIEHUNGSDIREKTION
Publication of DE68923362D1 publication Critical patent/DE68923362D1/de
Application granted granted Critical
Publication of DE68923362T2 publication Critical patent/DE68923362T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
DE68923362T 1988-11-04 1989-11-02 Wachstumsregelfaktoren für neuriten. Expired - Lifetime DE68923362T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26794188A 1988-11-04 1988-11-04
US07/401,212 US5684133A (en) 1988-11-04 1989-08-30 Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions
PCT/EP1989/001321 WO1990005191A1 (en) 1988-11-04 1989-11-02 Neurite growth regulatory factors

Publications (2)

Publication Number Publication Date
DE68923362D1 DE68923362D1 (de) 1995-08-10
DE68923362T2 true DE68923362T2 (de) 1996-03-28

Family

ID=26952762

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68923362T Expired - Lifetime DE68923362T2 (de) 1988-11-04 1989-11-02 Wachstumsregelfaktoren für neuriten.

Country Status (8)

Country Link
US (2) US6025333A (de)
EP (1) EP0396719B1 (de)
KR (1) KR100196540B1 (de)
AT (1) ATE124726T1 (de)
AU (2) AU652537B2 (de)
DE (1) DE68923362T2 (de)
DK (1) DK160190A (de)
WO (1) WO1990005191A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU652537B2 (en) * 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
WO1993000427A2 (en) * 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
AU5891394A (en) * 1993-02-11 1994-08-29 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
HUP9900060A3 (en) * 1995-04-19 2001-08-28 Acorda Therapeutics New York Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6576441B1 (en) 1995-12-06 2003-06-10 Sumitomo Pharmaceuticals Company, Limited Semaphorin Z and gene encoding the same
AU4136797A (en) 1996-09-11 1998-04-02 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin gene: semaphorin y
EP0945505A4 (de) 1996-10-09 2002-11-27 Sumitomo Pharma Neues semaphorin-gen: semaphorin w
EP0960888A4 (de) 1996-11-15 2002-10-16 Sumitomo Pharma Neue semaphorin-gene (i)
JP2002518010A (ja) 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
CN1721444A (zh) * 1998-11-06 2006-01-18 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ520065A (en) 2000-01-12 2006-02-24 Univ Yale Nogo receptor-mediated blockade of axonal growth
ATE458815T1 (de) * 2000-10-06 2010-03-15 Univ Yale Homologe des nogo rezeptors
EP1805209A4 (de) * 2004-10-01 2008-04-02 Univ Yale Nogo-a polypeptidfragmente, variante von nogo receptor-1 polypeptiden und verwendung
US20060217324A1 (en) * 2005-01-24 2006-09-28 Juergen Soutschek RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof
WO2007008732A2 (en) * 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
US7772200B2 (en) 2005-07-21 2010-08-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeted to the Rho-A gene
CA2619406A1 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
KR100756423B1 (ko) 2005-10-27 2007-09-07 한국과학기술연구원 성선자극호르몬 수용체를 바이오마커로 이용한 마이엘린의탐색방법
BRPI0618609A2 (pt) * 2005-11-16 2011-09-06 Novartis Ag biomarcadores para tratamento com anticorpo anti-nogo-a em danos à medula espinhal
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
CN101969999B (zh) * 2006-11-21 2017-03-22 雅培制药有限公司 抗nogo‑66受体(ngr)的中和单克隆抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287184A (en) * 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) * 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
CA1173823A (en) * 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0155433A1 (de) * 1984-03-23 1985-09-25 Adriano Fontana Immunsuppressionsfaktor
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
US4803163A (en) * 1984-06-04 1989-02-07 E. I. Du Pont De Nemours And Company Preparation of a protein fraction exhibiting cell growth-inhibiting activity
EP0233838A3 (de) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neuriten stimulierender Faktor und Prozess für seine Herstellung
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU652537B2 (en) * 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors

Also Published As

Publication number Publication date
EP0396719B1 (de) 1995-07-05
DE68923362D1 (de) 1995-08-10
AU680932B2 (en) 1997-08-14
AU7435494A (en) 1994-12-15
US6025333A (en) 2000-02-15
EP0396719A1 (de) 1990-11-14
US6103232A (en) 2000-08-15
DK160190A (da) 1990-09-03
WO1990005191A1 (en) 1990-05-17
DK160190D0 (da) 1990-07-03
KR100196540B1 (ko) 1999-06-15
ATE124726T1 (de) 1995-07-15
KR900702050A (ko) 1990-12-05
AU4528089A (en) 1990-05-28
AU652537B2 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
DE68923362T2 (de) Wachstumsregelfaktoren für neuriten.
HUT73799A (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
Peltonen et al. A defect in the structure of type I procollagen in a patient who had osteogenesis imperfecta: excess mannose in the COOH-terminal propeptide.
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
DE69429721D1 (de) Verwendung von neuronalen fötalen zellinien für transplantationstherapie
DE69535221D1 (de) Cardiotrophin und verwendung davon
ATE288490T1 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
WO1993000427A3 (en) Neurite growth regulatory factors
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
WO2003103573A3 (en) METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
Balasubramanian Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
ES8702910A1 (es) Procedimiento para la obtencion de benzodiazepinas.
WO2024040030A3 (en) Treating protein misfolding disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition